Neil Grubert

Independent pharmaceutical consultant, trainer and writer with a focus on pricing, reimbursement and market access trends around the world

[Neil Grubert @NeilGrubert]

What role does tendering play in promoting competition in pharmaceutical markets? A new study by the OECD, co-funded by the European Commission, examines the use of tendering and other practices to enhance competition in patent-protected markets (…https://t.co/92NkvFBfCw

[Neil Grubert @NeilGrubert]

VPAS negotiations will not include the British Generic Manufacturers Association (BGMA) following the High Court's rejection of an application to be a party to the discussions alongside the #ABPI.

The judge ruled that “no voluntary scheme which is the p…https://t.co/dGZ5GSTxdN

[Neil Grubert @NeilGrubert]

HTA agencies should have more interaction with the leaders of large pharmaceutical companies but also be more attuned to the needs of highly innovative start-ups, according to Meindert Boysen, Head of International Affairs at NICE. He shared his thoughts…https://t.co/EhT6OqtR7C

[Neil Grubert @NeilGrubert]

An innovative managed entry model for gene therapies that could save money relative to existing therapies has been proposed by CSL Behring in Germany. The mechanism would apply to single-administration, potentially curative therapies that replace chronic…https://t.co/RJecZw2eDt

[Neil Grubert @NeilGrubert]

Measures to streamline access to innovative medicines will be introduced by the French government in the coming months. The Ministry of Health (MoH) has responded to criticism of aspects of the French access environment highlighted in the first report iss…https://t.co/ja2CcXJ7AJ

[Neil Grubert @NeilGrubert]

“Regulatory approval is too often equated with superiority over existing treatments. The fact that new does not necessarily mean better needs to be clearly communicated to both patients and clinicians.” This statement is made by Beater Wieseler, Head of t…https://t.co/cpYJ5MftuZ

[Neil Grubert @NeilGrubert]

China will offer “more development opportunities for foreign-funded enterprises, including the pharmaceutical industry,” according to Commerce Minister Wang Wentao. He was speaking at a roundtable meeting with representatives of 12 multinational life scie…https://t.co/nxzS0Ihydy

[Neil Grubert @NeilGrubert]

What information are EU payers and P&R agencies sharing with each other? The recently published minutes of the March 2023 meeting of the National Competent Authorities on Pricing and Reimbursement (NCAPR) provides some fascinating insights.

The European…https://t.co/aQxTMKsx8C

[Neil Grubert @NeilGrubert]

How strongly will Germany influence the preparations for EU joint HTA, which takes effect in January 2025? A recent statement from the GBA offers some clues.

The statement notes that “the implementation and shaping of the EU HTA Regulation is the respon…https://t.co/VCdlybBcJ4

[Neil Grubert @NeilGrubert]

Germany should adopt a profit cap and cost-plus pricing for pharmaceuticals in the view of the head of the country’s largest statutory health insurance fund. Jens Baas, the CEO of the Techniker Krankenkasse, set out his ideas in an interview with Handelsb…https://t.co/GV4SkqLSDB

[Neil Grubert @NeilGrubert]

Some interesting insights on drug pricing and HTA in the UK are provided by recently published minutes of a high-level meeting in February 2023 regarding the working of the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS). Among other topi…https://t.co/qsquaCOB6k

[Neil Grubert @NeilGrubert]

What are the likely timelines for revision of the EU general pharmaceutical legislation—and the prospects of completing the process before elections to the European Parliament in 2024? The Spanish news agency EFE has identified key milestones that suggest…https://t.co/ySYfD9ybiZ

[Neil Grubert @NeilGrubert]

A US list price of $2.9mn has been announced by BioMarin for Roctavian (valoctocogene roxaparvovec), the first gene therapy for severe haemophilia A, following FDA approval of the treatment. The company has worked with public and private payers on its rei…https://t.co/cnGECpRQID

[Neil Grubert @NeilGrubert]

Access delays for new medicines in France are growing—primarily because of the time taken to negotiate prices and publish that information in the Official Journal, according to a new analysis by Leem, the pharmaceutical industry association. The median ti…https://t.co/1ikuGKdRsV

[Neil Grubert @NeilGrubert]

Access delays for new medicines in France are growing—primarily because of the time taken to negotiate prices and publish that information in the Official Journal, according to a new analysis by Leem, the pharmaceutical industry association. The median ti…https://t.co/pHycamCtxj

[Neil Grubert @NeilGrubert]

Improved access to innovative medicines will be a priority for a Spanish government led by the Popular Party (PP) if it wins the general election on 23rd July 2023. The party has just published a “Decalogue of Health Measures” that includes several polici…https://t.co/QX05oU05V9

[Neil Grubert @NeilGrubert]

A new cross-border HTA partnership has been formed between NICE and Taiwan’s National Health Insurance Administration (NHIA). A memorandum of understanding was signed on 18th May 2023 during a visit by NHIA representatives to NICE’s offices.

The visit i…https://t.co/zK7WDkMtLw

[Neil Grubert @NeilGrubert]

What are the potential benefits of greater use of precision medicine (PM) and precision health (PH) in Europe? A new report from Charles River Associates for #EFPIA examines the impact these approaches could have in four disease areas: breast and lung can…https://t.co/rwynTJI7Gr

[Neil Grubert @NeilGrubert]

What impact is RWE having on regulatory decision making in the EU and how might it affect HTA in the future? A new report from EMA (https://t.co/zIk8rUbrPe) offers some insights.

The report covers the period September 2021 to February 2022. Sixty-one RW…https://t.co/x7czBV3gEt

[Neil Grubert @NeilGrubert]

A list price of $3.2 million has been announced for the first gene therapy for Duchenne muscular dystrophy (DMD). The FDA has granted Sarepta’s Elevidys (delandistrogene moxeparvovec-rokl) accelerated approval for children aged 4-5 who can still walk and…https://t.co/p0pmhwC0bY